Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,158 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Aug 15, 2022 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| A Study to Evaluate Vaccines Against COVID-19 in the Real World |
| withdrawn |
| — |
| 0 |
| Humanity & Health Medical Group LimitedOTHER |
| 1 |
| Aug 3, 2022 |
| clinicaltrials |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | withdrawn | N/A | 0 | Xoft, Inc.INDUSTRY | 0 | Aug 2, 2022 | clinicaltrials |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | withdrawn | — | 0 | Beth Israel Deaconess Medical CenterOTHER | 0 | Jul 21, 2022 | clinicaltrials |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT04849377 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | withdrawn | Phase 2 | 0 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Lion TCR Pte. Ltd.INDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Jun 9, 2022 | clinicaltrials |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | withdrawn | — | 0 | University Hospital, GrenobleOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04831567 | Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors(MIBNET) | withdrawn | Phase 2 | 0 | AC Camargo Cancer CenterOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | withdrawn | Phase 3 | 0 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | withdrawn | Phase 2 | 0 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04003025 | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01) | withdrawn | — | 0 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT04266470 | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT04231929 | BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.(BIOPEARL-FIRST) | withdrawn | N/A | 0 | Terumo Europe N.V.INDUSTRY | 1 | Mar 28, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 / Phase 3 | 0 | MacroGenicsINDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .(VERU-111) | withdrawn | Phase 2 | 0 | Veru Inc.INDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | withdrawn | Phase 2 | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05099952 | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT04672876 | Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 0 | Dec 17, 2021 | clinicaltrials |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | withdrawn | Phase 2 | 0 | 4SC AGINDUSTRY | 0 | Nov 18, 2021 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | withdrawn | N/A | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | withdrawn | Phase 2 | 0 | Antonio FojoOTHER | 0 | Oct 13, 2021 | clinicaltrials |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab | withdrawn | Early Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 0 | Oct 8, 2021 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer(PANDoRA) | withdrawn | Phase 2 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors | withdrawn | — | 0 | TScan Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01967927 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy | withdrawn | Early Phase 1 | 0 | University of ArkansasOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 15, 2022source: clinicaltrials